Rofecoxib, Merck, and the FDA

N Engl J Med. 2004 Dec 30;351(27):2875-8; author reply 2875-8. doi: 10.1056/NEJM200412303512719.
No abstract available

Publication types

  • Comment
  • Historical Article
  • Letter

MeSH terms

  • Cardiovascular Diseases / chemically induced*
  • Cardiovascular Diseases / mortality
  • Cyclooxygenase Inhibitors / adverse effects*
  • Cyclooxygenase Inhibitors / history
  • Drug Approval / history*
  • Drug Industry / history*
  • History, 20th Century
  • History, 21st Century
  • Humans
  • Lactones / adverse effects*
  • Lactones / history
  • Randomized Controlled Trials as Topic / history
  • Sulfones / adverse effects*
  • Sulfones / history
  • United States
  • United States Food and Drug Administration

Substances

  • Cyclooxygenase Inhibitors
  • Lactones
  • Sulfones
  • rofecoxib